ADPT Adaptive Biotechnologies Corporation

27.93USD-0.43%Mkt Cap: 4.52B USDP/E: —

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a su…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap4.52B USD
Enterprise Value4.66B USD
Revenue (TTM)298.01M USD
Gross Profit205.62M USD
Net Income (TTM)-59.50M USD
Revenue/Share1.90 USD
Last Price27.93 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees624
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-598.46
PEG—
EV/EBITDA-141.71
EV/Revenue15.63
P/S15.17
P/B25.60
EPS (TTM)-0.45 USD
EPS (Forward)-0.05 USD
52W Range
12.0079% of range32.13
52W High32.13 USD
52W Low12.00 USD
Profitability
Gross Margin74.24%
Oper. Margin-16.18%
EBITDA Margin-11.03%
Profit Margin-21.48%
ROE-27.19%
ROA-11.60%
ROIC-58.48%
ROCE-13.51%
Growth
Revenue Growth-10.70%
Earnings Growth-70.10%
Cash Flow & Leverage
Operating CF-45.99M USD
CapEx (TTM)2.96M USD
FCF Margin4.84%
FCF Yield0.32%
Net Debt110.02M USD
Net Debt/EBITDA-3.35
Net Debt/FCF7.62
Balance Sheet
Debt/Equity0.36
Current Ratio3.97
Quick Ratio3.72
Book Value/Sh1.09 USD
Cash/Share1.85 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.86 USD
Upside (mean)+21.2%
Target Range30.00 USD – 35.00 USD
30.00+21.2% to mean35.00
# Analysts7
Ownership
Shares Out.161.88M
Float127.87M
Insiders1.21%
Institutions106.94%
Short Interest
Short Ratio5.4d
Short % Float8.93%
Short % Out.7.09%
Shares Short11.48M
Short (prev mo.)11.84M
Technical
SMA 5027.14 (+2.9%)
SMA 20020.23 (+38.0%)
Beta2.15
S&P 52W Chg12.00%
Avg Vol (30d)2.18M
Avg Vol (10d)2.55M
Technical Indicators
RSI (14)51.7
MACD0.5481
MACD Signal0.6106
MACD Hist.-0.0625
BB Upper30.67 USD
BB Middle27.92 USD
BB Lower25.17 USD
BB Width19.72%
ATR (14)1.677 USD
Vol Ratio (20d)1.06x

About Adaptive Biotechnologies (NASDAQ: ADPT)

›

Adaptive Biotechnologies (NASDAQ: ADPT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 624 employees.

The shares were at 27.93 USD on 20 November 2026, up 60.9% over 52 weeks. Its 52-week range is 12.00 USD to 32.13 USD: the price is 13.1% below the high and 132.8% above the low.

Its market capitalisation is 4.52B USD.

Adaptive Biotechnologies reports return on equity of -27.2%, an operating margin of -16.2% and revenue down 10.7% year over year.

Its debt exceeds its cash by 110.02M USD, a debt-to-equity ratio of 0.36. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 33.86 USD is 21.2% above the current price. The next earnings report is expected on 4 February 2027.